Molecular targeting of angiogenesis for imaging and therapy.
Angiogenesis, i.e. the proliferation of new blood vessels from pre-existing ones, is an underlying process in many human diseases, including cancer, blinding ocular disorders and rheumatoid arthritis. The ability to selectively target and interfere with neovascularisation would potentially be useful in the diagnosis and treatment of angiogenesis-related diseases. This review presents the authors' views on some of the most relevant markers of angiogenesis described to date, as well as on specific ligands which have been characterised in pre-clinical animal models and/or clinical studies. Furthermore, we present an overview on technologies which are likely to have an impact on the way molecular targeting of angiogenesis is performed in the future.
Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland.
Simon S
SS
Brack
Ludger M
LM
Dinkelborg
Dario
D
Neri
D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000378:metabolism*; D016503:Drug Delivery Systems / Q000379:methods; D006801:Humans; D007249:Inflammation / Q000000981:diagnostic imaging* / Q000628:therapy*; D025202:Molecular Diagnostic Techniques / Q000379:methods*; D015336:Molecular Probe Techniques; D015335:Molecular Probes; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000628:therapy*; D011877:Radionuclide Imaging
D015415:Biomarkers; D014408:Biomarkers, Tumor; D015335:Molecular Probes